6B7Z

Cryo-EM structure of human insulin degrading enzyme in complex with FAB H11 heavy chain and FAB H11 light chain

Summary for 6B7Z

• Entry DOI: 10.2210/pdb6b7z/pdb
• Related: 6B3Q 6B70 6B7Y
• EMDB information: 7041 7062 7066
• Descriptor: Insulin-degrading enzyme, FAB H11 heavy chain, FAB H11 light chain (3 entities in total)
• Functional Keywords: ide, insulin degrading enzyme, amyloid beta, biosynthetic protein, hydrolase-immune system complex, hydrolase/immune system
• Biological source: Homo sapiens (Human); More
• Total number of polymer chains: 6
• Total formula weight: 316023.68

Authors

Liang, W.G.,Zhang, Z.,Bailey, L.J.,Kossiakoff, A.A.,Tan, Y.Z.,Wei, H.,Carragher, B.,Potter, S.C.,Tang, W.J. (deposition date: 2017-10-05, release date: 2018-01-10, Last modification date: 2024-10-09)

Primary citation

Zhang, Z.,Liang, W.G.,Bailey, L.J.,Tan, Y.Z.,Wei, H.,Wang, A.,Farcasanu, M.,Woods, V.A.,McCord, L.A.,Lee, D.,Shang, W.,Deprez-Poulain, R.,Deprez, B.,Liu, D.R.,Koide, A.,Koide, S.,Kossiakoff, A.A.,Li, S.,Carragher, B.,Potter, C.S.,Tang, W.J.
Ensemble cryoEM elucidates the mechanism of insulin capture and degradation by human insulin degrading enzyme.
Elife, 7:-, 2018

PubMed Abstract: Insulin degrading enzyme (IDE) plays key roles in degrading peptides vital in type two diabetes, Alzheimer's, inflammation, and other human diseases. However, the process through which IDE recognizes peptides that tend to form amyloid fibrils remained unsolved. We used cryoEM to understand both the apo- and insulin-bound dimeric IDE states, revealing that IDE displays a large opening between the homologous ~55 kDa N- and C-terminal halves to allow selective substrate capture based on size and charge complementarity. We also used cryoEM, X-ray crystallography, SAXS, and HDX-MS to elucidate the molecular basis of how amyloidogenic peptides stabilize the disordered IDE catalytic cleft, thereby inducing selective degradation by substrate-assisted catalysis. Furthermore, our insulin-bound IDE structures explain how IDE processively degrades insulin by stochastically cutting either chain without breaking disulfide bonds. Together, our studies provide a mechanism for how IDE selectively degrades amyloidogenic peptides and offers structural insights for developing IDE-based therapies.

PubMed: 29596046
DOI: 10.7554/eLife.33572

Experimental method

ELECTRON MICROSCOPY (6.5 Å)